Grayson-Caprio Terry
Known title: DirectorCIK: 0001867557
Grayson-Caprio Terry's purchase track record
How the stock did after each of Grayson-Caprio Terry's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since December 13, 2021
Stock higher 6 months later
40%
3 months: 60%
Median 6-month return
-7.5%
3 months: +1.6%
Beat the S&P 500
40%
median -5.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/18/2024 | SFST | $7K | -14.1% | -8.3% | +1.8% |
| 5/4/2023 | SFST | $21K | +39.8% | +30.4% | +6.3% |
| 8/1/2022 | SFST | $44K | +1.6% | -7.5% | -2.5% |
| 5/16/2022 | SFST | $43K | +10.7% | +10.8% | -1.3% |
| 12/13/2021 | SFST | $6K | -7.3% | -27.7% | -19.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SFST | ▲ Buy | Grant | 310 | $0 | 6/1/2026 | View on chart |
| DCH | ▲ Buy | Grant | 29,773 | $0 | 4/30/2026 | View on chart |
| SFST | ▲ Buy | Grant | 485 | $0 | 6/1/2025 | View on chart |
| DCH | ▲ Buy | Grant | 39,474 | $150K | 5/1/2025 | View on chart |
| SFST | ▲ Buy | Open Market | 160 | $7K | 12/18/2024 | View on chart |
| SFST | ▲ Buy | Open Market | 1,000 | $21K | 5/4/2023 | View on chart |
| SFST | ▲ Buy | Open Market | 500 | $22K | 8/1/2022 | View on chart |
| SFST | ▲ Buy | Open Market | 500 | $22K | 8/1/2022 | View on chart |
| SFST | ▲ Buy | Open Market | 500 | $21K | 5/16/2022 | View on chart |
| SFST | ▲ Buy | Open Market | 500 | $21K | 5/16/2022 | View on chart |
| SFST | ▲ Buy | Open Market | 100 | $6K | 12/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Dauch names new CFO, faces lower price targets from Barclays and UBS
Dauch Corporation announced a financial leadership change, appointing Nathan Iles as CFO effective December 1 to succeed Christopher May. This executive shift coincides with recent analyst actions, as both Barclays and UBS lowered their price targets to $8 while maintaining their respective ratings. The stock has experienced a significant decline since February, currently trading near its 52-week low, which has prompted discussions about potential undervaluation despite the recent downward revisions.
Dauch names new CFO, faces lower price targets from Barclays and UBS. Dauch Corporation announced a financial leadership change, appointing Nathan Iles as CFO effective December 1 to succeed Christopher May. This executive shift coincides with recent analyst actions, as both Barclays and UBS lowered their price targets to $8 while maintaining their respective ratings. The stock has experienced a significant decline since February, currently trading near its 52-week low, which has prompted discussions about potential undervaluation despite the recent downward revisions.